CytomX Commences Phase 1 Clinical Trial with Patient Dosing of EpCAM-Targeted ADC CX-2051 for Advanced Solid Tumors

CytomX Therapeutics, a biotech firm specializing in targeted biologics, has initiated a Phase 1 clinical trial for CX-2051, an antibody drug conjugate (ADC) aimed at treating advanced solid tumors. The drug targets the epithelial cell adhesion molecule (EpCAM), which is prevalent in various cancers such as colorectal, gastric, endometrial, and ovarian. 

CX-2051 incorporates a potent derivative of camptothecin, a topoisomerase-1 inhibitor with a proven track record in cancer treatment. The study, registered as NCT06265688, will assess the safety and initial anti-tumor effects of CX-2051, with the goal of establishing a clinical proof of concept that may lead to further trials in 2025. 

Wayne Chu, the company's chief medical officer, emphasized the significance of EpCAM as a target and the potential of CX-2051 in treating specific cancer types.CytomX is advancing a pipeline of therapies that leverage its PROBODY® platform to enhance the safety and efficacy of treatments. Their pipeline includes CX-904, an ADC targeting EGFR on tumor cells, and CX-801, a cytokine with broad applicability in various tumor types. The company has collaborations with industry leaders such as Amgen, Astellas, and Bristol Myers Squibb. The company's forward-looking statements highlight the uncertainty inherent in drug development, including the novel nature of the PROBODY® technology and the risks associated with clinical trials and regulatory processes. 

CytomX cautions against relying on these statements due to the unpredictable nature of drug development and the potential for higher costs and unforeseen expenses. The company's trademarks, including PROBODY®, are registered in the U.S.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!